Skip to content

Testosterone Undecanoate

FDA-approved product (injectable, intramuscular), marketed as Aveed, Jatenzo, Kyzatrex and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Testosterone Undecanoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Hypogonadism
  • Hypogonadotropic hypogonadism
  • Klinefelter's syndrome
  • Neoplasm
  • Orchitis
  • Physiological sexual disorder
  • Sexual dysfunction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
3-oxoandrosten (4) derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Testosterone Undecanoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Hormone Treatment in Growth Hormone and Testosterone Deficient Patients

    NCT01397500 · start 2011-11

    Registered record
    Registry ID
    NCT01397500
    Conditions
    Hormone Deficiency
    Interventions
    Genotropin; Testosterone undecannoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-11
    Completion
    2015-03
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone Deficiency
    InterventionGenotropin; Testosterone undecannoate
    PhasePhase 2
    Registry statusTerminated
  • Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

    NCT01403116 · start 2011-07

    Registered record
    Registry ID
    NCT01403116
    Conditions
    Male Hypogonadism
    Interventions
    Oral testosterone undecanoate; topical testosterone gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-07
    Completion
    2013-09
    Enrolment
    325

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMale Hypogonadism
    InterventionOral testosterone undecanoate; topical testosterone gel
    PhasePhase 3
    Registry statusCompleted
  • Benefit of the Treatment With Testosterone in Chronic Heart Failure Testosterone Deficiency Subjects

    NCT01813201 · start 2011-03

    Registered record
    Registry ID
    NCT01813201
    Conditions
    Heart Failure
    Interventions
    Testosterone undecanoate; Saline isotonic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2014-03
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionTestosterone undecanoate; Saline isotonic solution
    PhasePhase 4
    Registry statusCompleted
  • Effects of Sex Steroid Hormones on Human Brain Function, Structure and Connectivity

    NCT01292785 · start 2011-01

    Registered record
    Registry ID
    NCT01292785
    Conditions
    Gender Identity Disorder
    Interventions
    Hormones
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-01
    Completion
    2015-04
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGender Identity Disorder
    InterventionHormones
    PhaseNot recorded
    Registry statusCompleted
  • NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)

    NCT01092858 · start 2010-09

    Registered record
    Registry ID
    NCT01092858
    Conditions
    Hypogonadism
    Interventions
    Testosterone Undeconate (Nebido, BAY86-5037); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-09
    Completion
    2011-07
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism
    InterventionTestosterone Undeconate (Nebido, BAY86-5037); Placebo
    PhasePhase 4
    Registry statusTerminated
  • Sex Steroids and the Serotonin Transporter

    NCT01065220 · start 2010-02

    Registered record
    Registry ID
    NCT01065220
    Conditions
    Transsexualism
    Interventions
    Testolactone undecanoate; Lynestrenol; Cyproterone Acetate; Estradiol; 5-alpha reductase inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-02
    Completion
    2014-01
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTranssexualism
    InterventionTestolactone undecanoate; Lynestrenol; Cyproterone Acetate; Estradiol +1 more
    PhasePhase 4
    Registry statusCompleted
  • Oral T7 Oral Testosterone in Man

    NCT00842751 · start 2009-07

    Registered record
    Registry ID
    NCT00842751
    Conditions
    Healthy Males; Male Contraceptive
    Interventions
    First Intervention (7 days); First Washout (7 days); Second Intervention (7 days); Third Intervention (7 days); Second wash-out period
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07
    Completion
    2009-12
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Males; Male Contraceptive
    InterventionFirst Intervention (7 days); First Washout (7 days); Second Intervention (7 days); Third Intervention (7 days) +1 more
    PhasePhase 2
    Registry statusCompleted
  • Pharmacokinetic Study to Determine Time to Steady-state

    NCT00911586 · start 2009-07

    Registered record
    Registry ID
    NCT00911586
    Conditions
    Male Hypogonadism; Primary Hypogonadism; Secondary Hypogonadism
    Interventions
    Testosterone undecanoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07
    Completion
    2010-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMale Hypogonadism; Primary Hypogonadism; Secondary Hypogonadism
    InterventionTestosterone undecanoate
    PhasePhase 2
    Registry statusCompleted
  • Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation

    NCT00924612 · start 2009-07

    Registered record
    Registry ID
    NCT00924612
    Conditions
    Male Hypogonadism
    Interventions
    Oral testosterone undecanoate (containing 300 mg T)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07
    Completion
    2010-07
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMale Hypogonadism
    InterventionOral testosterone undecanoate (containing 300 mg T)
    PhasePhase 2
    Registry statusCompleted
  • Exercise Training and Testosterone Replacement in Heart Failure Patients

    NCT01852994 · start 2009-07

    Registered record
    Registry ID
    NCT01852994
    Conditions
    Heart Failure
    Interventions
    Testosterone replacement; Exercise training
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-07
    Completion
    2015-07
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionTestosterone replacement; Exercise training
    PhasePhase 4
    Registry statusCompleted
  • Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men

    NCT00695110 · start 2008-06

    Registered record
    Registry ID
    NCT00695110
    Conditions
    Hypogonadism
    Interventions
    Oral testosterone undecanoate (TU) (300 mg T equivalents/dose); Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose); Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food); Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-06
    Completion
    2009-08
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism
    InterventionOral testosterone undecanoate (TU) (300 mg T equivalents/dose); Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose); Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food); Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
    PhasePhase 2
    Registry statusCompleted
  • Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men

    NCT02697188 · start 2007-11

    Registered record
    Registry ID
    NCT02697188
    Conditions
    Hypogonadism
    Interventions
    Testosterone undecanoate; Testosterone enanthate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-11
    Completion
    2008-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism
    InterventionTestosterone undecanoate; Testosterone enanthate
    PhasePhase 2
    Registry statusCompleted
  • Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina

    NCT00131183 · start 2005-09

    Registered record
    Registry ID
    NCT00131183
    Conditions
    Angina Pectoris
    Interventions
    Nebido
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-09
    Completion
    2008-05
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAngina Pectoris
    InterventionNebido
    PhasePhase 4
    Registry statusCompleted
  • Testosterone and Its Metabolites in GID

    NCT00146146 · start 2005-05

    Registered record
    Registry ID
    NCT00146146
    Conditions
    Transsexualism
    Interventions
    testosterone undecanoate alone; testosterone undecanoate plus letrozole; testosterone undecanoate plus dutasteride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-05
    Completion
    2008-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTranssexualism
    Interventiontestosterone undecanoate alone; testosterone undecanoate plus letrozole; testosterone undecanoate plus dutasteride
    PhasePhase 3
    Registry statusCompleted
  • Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)

    NCT00403793 · start 2003-10

    Registered record
    Registry ID
    NCT00403793
    Conditions
    Contraception
    Interventions
    etonogestrel with testosterone undecanoate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-10
    Completion
    2006-12
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    Interventionetonogestrel with testosterone undecanoate; Placebo
    PhasePhase 2
    Registry statusCompleted